Mersana Therapeutics (MRSN)
(Delayed Data from NSDQ)
$2.11 USD
-0.02 (-0.94%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $2.10 -0.01 (-0.47%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Mersana Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -171.67 | -204.21 | -170.06 | -88.05 | -28.21 |
Depreciation/Amortization & Depletion | -3.05 | -0.54 | 0.86 | 0.92 | 1.02 |
Net Change from Assets/Liabilities | -15.98 | 133.10 | 10.09 | 5.11 | -45.53 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 21.82 | 22.29 | 19.13 | 7.32 | 4.98 |
Net Cash From Operating Activities | -168.88 | -49.36 | -139.99 | -74.70 | -67.74 |
Property & Equipment | -2.17 | -2.20 | -0.65 | -0.47 | -0.61 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 122.05 | -150.52 | 0.00 | 37.50 | -26.69 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 119.88 | -152.72 | -0.65 | 37.03 | -27.29 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 1.55 | 2.40 | 2.48 | 167.69 | 92.83 |
Issuance (Repayment) of Debt | -0.41 | -0.27 | 18.34 | -0.31 | 4.88 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 93.54 | 150.89 | 42.83 | 63.04 | 0.00 |
Net Cash from Financing Activities | 94.68 | 153.02 | 63.65 | 230.41 | 97.70 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 45.68 | -49.06 | -76.99 | 192.74 | 2.67 |
Cash at Beginning of Period | 129.36 | 178.43 | 255.42 | 62.67 | 60.01 |
Cash at End of Period | 175.04 | 129.36 | 178.43 | 255.42 | 62.67 |
Diluted Net EPS | -1.48 | -2.18 | -2.41 | -1.43 | -0.65 |
Fiscal Year End for Mersana Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -43.57 | -19.31 | -171.67 | -152.13 |
Depreciation/Amortization & Depletion | NA | -1.58 | -0.69 | -3.05 | -3.17 |
Net Change from Assets/Liabilities | NA | -18.60 | -17.39 | -15.98 | 0.79 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 9.24 | 4.73 | 21.82 | 17.59 |
Net Cash From Operating Activities | NA | -54.51 | -32.66 | -168.88 | -136.92 |
Property & Equipment | NA | -0.13 | -0.13 | -2.17 | -1.78 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -66.90 | -72.42 | 122.05 | 101.52 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -67.03 | -72.55 | 119.88 | 99.74 |
Uses of Funds
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 0.31 | 0.05 | 1.55 | 1.39 |
Issuance (Repayment) of Debt | NA | -0.11 | -0.07 | -0.41 | -0.35 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 5.78 | 5.85 | 93.54 | 93.54 |
Net Cash from Financing Activities | NA | 5.98 | 5.83 | 94.68 | 94.58 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -115.56 | -99.38 | 45.68 | 57.40 |
Cash at Beginning of Period | NA | 175.04 | 175.04 | 129.36 | 129.36 |
Cash at End of Period | NA | 59.48 | 75.66 | 175.04 | 186.76 |
Diluted Net EPS | NA | -0.20 | -0.16 | -0.14 | -0.35 |